Quantcast

Towards developing a vaccine for rheumatic heart disease.

Research paper by Geethanjali Devadoss GD Gandhi, Navaneethakrishnan N Krishnamoorthy, Ussama M Abdel UMA Motal, Magdi M Yacoub

Indexed on: 04 Oct '17Published on: 04 Oct '17Published in: Global cardiology science & practice



Abstract

Rheumatic heart disease (RHD) is the most serious manifestations of rheumatic fever, which is caused by group A Streptococcus (GAS or Streptococcus pyogenes) infection. RHD is an auto immune sequelae of GAS pharyngitis, rather than the direct bacterial infection of the heart, which leads to chronic heart valve damage. Although antibiotics like penicillin are effective against GAS infection, improper medical care such as poor patient compliance, overcrowding, poverty, and repeated exposure to GAS, leads to acute rheumatic fever and RHD. Thus, efforts have been put forth towards developing a vaccine. However, a potential global vaccine is yet to be identified due to the widespread diversity of S. pyogenes strains and cross reactivity of streptococcal proteins with host tissues. In this review, we discuss the available vaccine targets of S. pyogenes and the significance of in silico approaches in designing a vaccine for RHD.